Does the immune system see tumors as foreign or self?

By D. Pardoll. Annual Review of Immunology, 2003

824 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/ecdd371b917aea9ac7b9280b0d6c6d974acaec2f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

Ido expression by dendritic cells: tolerance and tryptophan catabolism (2004, background): “It is increasingly clear that tumours can induce tolerance to their own antigen”
Galectins as modulators of tumour progression (2005, background): “Furthermore, tumour cells can release mediators believed to contribute to tumour cell evasion of the immune respons”
Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. (2007, background): “Many studies have established that cell-mediated innate and adaptive immunity are essential for preventing pri- mary tumor outgrowth and for rejecting transplanted tumors (Dunn et al., 2004a; Pardoll, 2003).”
Prevalence of FOXP3+ Regulatory T Cells Increases During the Progression of Pancreatic Ductal Adenocarcinoma and Its Premalignant Lesions (2006, background): “Such mechanisms might include direct deletion of immune effector cells by expression of deathinducing ligands, suppression of tumor-reactive T cells by regulatory T cells (TR), and tolerization of host T cells by crosspresentation of tumor-derived antigens (1, 2).”
Pancreatic ductal adenocarcinoma: Long-term survival does not equal cure (2012, neutral): “014 Negative 72 (76) 42 (68) 30 (91) Positive 23 (24) 20 (32) 3 (9) Perineural invasion NS No 23 (25) 14 (22) 9 (29) Yes 56 (60) 42 (68) 14 (45) Unknown 16 (15) 6 (10) 9 (26) Perivascular invasion NS No 32 (34) 18 (29) 13 (42) Yes 22 (23) 17 (28) 4 (13) Unknown 41 (43) 27 (43) 15 (45) Grade NS Moder”
Immunosuppressive strategies that are mediated by tumor cells. (2007, background): “This different view of tumor immunity has also raised the bar for cancer immunotherapy, since the barrier imposed by immune tolerance must be broken in order for the immune system to effectively recognize and eliminate tumors expressing mainly “self” (16) (Fig.”
The STATs of cancer — new molecular targets come of age (2004, background): “Tumour immune evasion and STAT3 signalling The ability of tumours to evade immune detection has not traditionally been included as a hallmark of cancer, despite rapid advances in the field of tumour immunolog”
The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. (2006, background): “Although it has been argued that tumors fail to provide sufficient pro-inflammatory responses, others have suggested otherwise (Matzinger, 1994; Pardoll, 2003).”
Immunostimulatory monoclonal antibodies for cancer therapy (2007, background): “Tolerance is mediated by either the elimination of the antigen-specific T cells through the induction of apoptosis (clonal deletion) or by functional paralysis of the antigen-specific T cells (anergy”
Metastasis: a question of life or death (2006, background): “However, a large number of observations — for example, that tumour development in immunodeficient and immunocompetent mice has similar kinetics, and that there is no systematic correlation between immunodeficiency and human cancer development — have raised concerns about this view and have indicated”